<DOC>
	<DOCNO>NCT01164059</DOCNO>
	<brief_summary>This study design compare efficacy drug tolerability two strategy treatment schizophrenia . The two strategy consist utilizing , one hand , conventional antipsychotic like haloperidol flupentixol , hand , new antipsychotic compound like olanzapine , quetiapine aripiprazole patient schizophrenia .</brief_summary>
	<brief_title>Clinical Effectiveness Newer Antipsychotics Comparison With Conventional Antipsychotics Schizophrenia</brief_title>
	<detailed_description>There agreement psychiatry community so-called atypical antipsychotic consider first choice treatment schizophrenic disorder . However , general superiority newer antipsychotic drug older conventional drug could clearly demonstrate recent control clinical trial . The discrepancy every day 's clinical perception result clinical trial raise question whether study perform far employed adequate methodological approach represent daily practice situation characterize wide variety duration type schizophrenic disorder , concomitant disease , medication . Moreover , study might focus adequately patient-relevant outcome variable . The present study project design answer open question . The innovative character study design 1. different neuroleptic strategy compare rather single antipsychotic drug , use 2. enhanced biometric design , provide choice treatment respect individual patient though trial randomise control double blind ; 3. clinically relevant endpoint quality life primary variable , 4. inclusion exclusion criterion lead study population represent clinical every day practice near possible . Another innovatory procedure serum level study drug record twice study . The author hope design might yield transfer effect clinical trial face similar problem .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Flupenthixol</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Flupenthixol decanoate</mesh_term>
	<criteria>Schizophrenia age 1865 year necessity establish new change antipsychotic treatment due unsatisfying result side effect write informed consent Exclusion Criteria ( amongst others ) : Known suspected hypersensitivity olanzapine , quetiapine , aripiprazole , flupentixol haloperidol Acute suicidal tendency `` Einwilligungsvorbehalt ( BGB ) '' `` Unterbringung ( PsychKG ) '' Epilepsy Organic psychosis Parkinson Disease Dementia History malignant neuroleptic syndrome QTc interval â‰¥ 0.5s / history congenital QTc prolongation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>atypical antipsychotic drug</keyword>
	<keyword>conventional antipsychotic drug</keyword>
	<keyword>olanzapine</keyword>
	<keyword>quetiapine</keyword>
	<keyword>aripiprazole</keyword>
	<keyword>haloperidol</keyword>
	<keyword>flupentixol</keyword>
</DOC>